Xu XE - Search Results

1

The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation.

Jin X, Xu XE, Jiang YZ, Liu YR, Sun W, Guo YJ, Ren YX, Zuo WJ, Hu X, Huang SL, Shen HJ, Lan F, He YF, Hu GH, Di GH, He XH, Li DQ, Liu S, Yu KD, Shao ZM. Jin X, et al. Among authors: xu xe. Sci Adv. 2019 Mar 6;5(3):eaat9820. doi: 10.1126/sciadv.aat9820. eCollection 2019 Mar. Sci Adv. 2019. PMID: 30854423 Free PMC article.

2

Loss of TIM50 suppresses proliferation and induces apoptosis in breast cancer.

Gao SP, Sun HF, Jiang HL, Li LD, Hu X, Xu XE, Jin W. Gao SP, et al. Among authors: xu xe. Tumour Biol. 2016 Jan;37(1):1279-87. doi: 10.1007/s13277-015-3878-0. Epub 2015 Aug 20. Tumour Biol. 2016. PMID: 26289846

3

Loss of COX5B inhibits proliferation and promotes senescence via mitochondrial dysfunction in breast cancer.

Gao SP, Sun HF, Jiang HL, Li LD, Hu X, Xu XE, Jin W. Gao SP, et al. Among authors: xu xe. Oncotarget. 2015 Dec 22;6(41):43363-74. doi: 10.18632/oncotarget.6222. Oncotarget. 2015. PMID: 26506233 Free PMC article.

4

Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer.

Liu YR, Jiang YZ, Xu XE, Hu X, Yu KD, Shao ZM. Liu YR, et al. Among authors: xu xe. Clin Cancer Res. 2016 Apr 1;22(7):1653-62. doi: 10.1158/1078-0432.CCR-15-1555. Epub 2016 Jan 26. Clin Cancer Res. 2016. PMID: 26813360

5

Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value.

Jiang YZ, Liu YR, Xu XE, Jin X, Hu X, Yu KD, Shao ZM. Jiang YZ, et al. Among authors: xu xe. Cancer Res. 2016 Apr 15;76(8):2105-14. doi: 10.1158/0008-5472.CAN-15-3284. Epub 2016 Mar 3. Cancer Res. 2016. PMID: 26921339

6

Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.

Liu YR, Jiang YZ, Xu XE, Yu KD, Jin X, Hu X, Zuo WJ, Hao S, Wu J, Liu GY, Di GH, Li DQ, He XH, Hu WG, Shao ZM. Liu YR, et al. Among authors: xu xe. Breast Cancer Res. 2016 Mar 15;18(1):33. doi: 10.1186/s13058-016-0690-8. Breast Cancer Res. 2016. PMID: 26975198 Free PMC article.

7

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.

Zuo WJ, Jiang YZ, Wang YJ, Xu XE, Hu X, Liu GY, Wu J, Di GH, Yu KD, Shao ZM. Zuo WJ, et al. Among authors: xu xe. Clin Cancer Res. 2016 Oct 1;22(19):4859-4869. doi: 10.1158/1078-0432.CCR-15-3036. Clin Cancer Res. 2016. PMID: 27697991

8

DSCAM-AS1 regulates the G₁ /S cell cycle transition and is an independent prognostic factor of poor survival in luminal breast cancer patients treated with endocrine therapy.

Sun W, Li AQ, Zhou P, Jiang YZ, Jin X, Liu YR, Guo YJ, Yang WT, Shao ZM, Xu XE. Sun W, et al. Among authors: xu xe. Cancer Med. 2018 Dec;7(12):6137-6146. doi: 10.1002/cam4.1603. Epub 2018 Nov 14. Cancer Med. 2018. PMID: 30430768 Free PMC article.

9

Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.

Liu XY, Ma D, Xu XE, Jin X, Yu KD, Jiang YZ, Shao ZM. Liu XY, et al. Among authors: xu xe. Theranostics. 2018 Dec 8;8(22):6386-6399. doi: 10.7150/thno.29164. eCollection 2018. Theranostics. 2018. PMID: 30613307 Free PMC article.

10

Transcriptome analysis of luminal breast cancer reveals a role for LOL in tumor progression and tamoxifen resistance.

Sun W, Xu X, Jiang Y, Jin X, Zhou P, Liu Y, Guo Y, Ma D, Zuo W, Huang S, He X, Shao Z. Sun W, et al. Int J Cancer. 2019 Aug 1;145(3):842-856. doi: 10.1002/ijc.32185. Epub 2019 Feb 19. Int J Cancer. 2019. PMID: 30720865

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

113 results

Search Page

Filters